Document Detail


How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
MedLine Citation:
PMID:  22422100     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80% of cases and is hereditary in 20-30% because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.
Authors:
Ka Kit Wong; Amanda M Laird; Amir Moubayed; Sotirios Chondrogiannis; Maria Cristina Marzola; Laura Evangelista; Milton D Gross; Domenico Rubello
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-13
Journal Detail:
Title:  Nuclear medicine communications     Volume:  -     ISSN:  1473-5628     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
a Department of Nuclear Medicine/Radiology b Department of Surgery, Section of General Surgery, Division of Endocrine Surgery, University of Michigan Hospital c Nuclear Medicine Service d Endocrine Surgery Service, Department of Veterans Affairs Health System, Ann Arbor, Michigan, USA e Department of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy f Nuclear Medicine Unit, Oncologic Venetian Institute - IRCCS, Padova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas.
Next Document:  A comprehensive understanding of melting temperature of nanowire, nanotube and bulk counterpart.